Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 1.00 |
| ▸ | RAB9A | P51151 | 6/20 | 1.00 |
| ▸ | CASP3 | P42574 | 1/20 | 1.00 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 1.00 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 1.00 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.88 |
| ▸ | MITF | O75030 | 1/20 | 0.88 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5532304 | 0.97 | NPC1 (0.95) | NPC1RAB9ACASP3SENP8SENP7 | |
| SCHEMBL6069179 | 0.94 | NR4A2 (1.00) | NPC1RAB9ACASP3SENP8SENP7 | |
| SCHEMBL2482452 | 0.94 | NR4A2 (1.00) | NPC1RAB9ACASP3SENP8SENP7 | |
| SCHEMBL11409495 | 0.94 | NPC1 (1.00) | NPC1RAB9ACASP3SENP8SENP7 | |
| SCHEMBL2482092 | 0.94 | NPC1 (1.00) | NPC1RAB9ACASP3SENP8SENP7 | |
| SCHEMBL11420874 | 0.92 | NPC1 (0.85) | NPC1RAB9ACASP3SENP8SENP7 | |
| SCHEMBL11413840 | 0.92 | NPC1 (0.85) | NPC1RAB9ACASP3SENP8SENP7 | |
| SCHEMBL11406007 | 0.92 | NPC1 (0.85) | NPC1RAB9ACASP3SENP8SENP7 | |
| SCHEMBL11420574 | 0.92 | NPC1 (0.85) | NPC1RAB9ACASP3SENP8SENP7 | |
| SCHEMBL2485014 | 0.90 | NR4A2 (0.83) | NPC1RAB9ACASP3SENP8SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| CN-120082056-A | Zirconium-based metal organic framework material and preparation method and application thereof | 南京工业大学 | 2025-06-03 | — | — | CN | claimed |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES INC (US) | 2025-05-01 | — | — | US | claimed |
| CN-222600093-U | Internet of things monitoring host | 深圳市宇泰科技有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-118834396-A | Metal-organic framework material suitable for propylene-propane adsorption separation and preparation method thereof | 南开大学 | 2024-10-25 | — | — | CN | claimed |
| CN-117952196-B | TBM tunneling parameter intelligent auxiliary decision-making system and method based on data-knowledge dual driving | 江河安澜工程咨询有限公司 | 2024-08-13 | — | — | CN | claimed |
| EP-3805238-B1 | NOVEL METAL-ORGANIC FRAMEWORK HAVING POROUS STRUCTURE FORMED FROM ZIRCONIUM CLUSTER SECONDARY BUILDING UNIT AND MULTI-BINDING LINKER | KOREA RES INST CHEMICAL TECH (KR) | 2024-07-03 | — | — | EP | claimed |
| WO-2024137858-A2 | METHODS AND COMPOSITIONS FOR ASSESSING COLORECTAL CANCER | SINGLERA GENOMICS INC. (US) | 2024-06-27 | — | — | WO | claimed |
| CN-221177728-U | Ethernet interface interconnection circuit | 成都天奥测控技术有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-117992310-A | Exception handling method for monitoring Tomcat | 暨南大学附属顺德医院(佛山市顺德区第二人民医院、佛山市顺德区冯尧敬纪念医院) | 2024-05-07 | — | — | CN | claimed |
| CN-117952196-A | TBM tunneling parameter intelligent auxiliary decision-making system and method based on data-knowledge dual driving | 江河安澜工程咨询有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-117812484-A | Vehicle-mounted hundred megaEthernet bifurcation circuit | 上海创时汽车科技有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-116636218-A | Video encoding and decoding using multi-directional intra-prediction | 北京达佳互联信息技术有限公司 | 2023-08-22 | — | — | CN | claimed |
| CN-116558729-A | Mould and method for checking air tightness of MDIP shell glass insulator | 中国电子科技集团公司第十三研究所 | 2023-08-08 | — | — | CN | claimed |
| WO-2023141595-A2 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES, INC. (US) | 2023-07-27 | — | — | WO | claimed |
| WO-2022221942-A1 | PREVENTION OF DRUG DIVERSION | BETTERLIFE PHARMA INC. (CA) | 2022-10-27 | — | — | WO | claimed |
| CN-113547997-B | Vehicle-mounted display device and system based on vehicle-mounted Ethernet interface | 东风汽车集团股份有限公司 | 2022-09-23 | — | — | CN | claimed |
| CN-114362114-A | Interface surge protection circuit of Ethernet physical layer chip | 裕太微电子股份有限公司 | 2022-04-15 | — | — | CN | claimed |
| EP-1418912-B1 | ISOXAZOLOPYRIDINONES | NOVARTIS AG (CH) | 2007-02-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | NPC1 1521/4885RAB9A 185/4885CASP3 1700/4885 |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | BDNF, HTR2A, NTRK2 | NPC1 2185/4885RAB9A 1320/4885CASP3 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.